[go: up one dir, main page]

WO2003057204A3 - Modulation of iamt (pimt or pcmt) in immune system - Google Patents

Modulation of iamt (pimt or pcmt) in immune system Download PDF

Info

Publication number
WO2003057204A3
WO2003057204A3 PCT/EP2003/000079 EP0300079W WO03057204A3 WO 2003057204 A3 WO2003057204 A3 WO 2003057204A3 EP 0300079 W EP0300079 W EP 0300079W WO 03057204 A3 WO03057204 A3 WO 03057204A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
immune system
iamt
pcmt
pimt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/000079
Other languages
French (fr)
Other versions
WO2003057204A2 (en
Inventor
Paul Andreas Compare Cloos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordic Bioscience AS
Original Assignee
Nordic Bioscience AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Bioscience AS filed Critical Nordic Bioscience AS
Priority to AU2003235799A priority Critical patent/AU2003235799A1/en
Publication of WO2003057204A2 publication Critical patent/WO2003057204A2/en
Publication of WO2003057204A3 publication Critical patent/WO2003057204A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Modulation of L-Isoaspartyl (D-Aspartyl) O-Methyltransferase activity in immune system associated cells enables the prevention or alleviation of an autoimmune response by decreasing self-antigen presentation or T-cell proliferation.
PCT/EP2003/000079 2002-01-08 2003-01-07 Modulation of iamt (pimt or pcmt) in immune system Ceased WO2003057204A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003235799A AU2003235799A1 (en) 2002-01-08 2003-01-07 Modulation of iamt (pimt or pcmt) in immune system

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34670902P 2002-01-08 2002-01-08
US60/346,709 2002-01-08
DKPA200200026 2002-01-08
DKPA200200026 2002-01-08

Publications (2)

Publication Number Publication Date
WO2003057204A2 WO2003057204A2 (en) 2003-07-17
WO2003057204A3 true WO2003057204A3 (en) 2004-02-05

Family

ID=26069124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000079 Ceased WO2003057204A2 (en) 2002-01-08 2003-01-07 Modulation of iamt (pimt or pcmt) in immune system

Country Status (2)

Country Link
AU (1) AU2003235799A1 (en)
WO (1) WO2003057204A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
FR2862661B1 (en) * 2003-11-26 2007-10-05 Agronomique Inst Nat Rech USE OF L-ISOASPARTYL METHYLTRANSFERASE AS A MARKER FOR LONGEVITY OF SEEDS.
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
DK2091948T3 (en) 2006-11-30 2012-07-23 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
EA022420B1 (en) 2010-03-10 2015-12-30 Пробиодруг Аг Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
GB1080979A (en) * 1964-11-03 1967-08-31 J U Geigy A G New thiepin and wxepin derivatives
GB1098347A (en) * 1964-06-29 1968-01-10 Geigy Ag J R New oxepin derivatives, their production and use
US3641056A (en) * 1970-01-06 1972-02-08 Ciba Geigy Corp 10-(aminomethyl)- and (aminoethyl)-dibenz (b f)oxepins
EP0726265A1 (en) * 1995-02-08 1996-08-14 Ciba-Geigy Ag 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity
WO1997045422A1 (en) * 1996-05-30 1997-12-04 Novartis Ag ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS
WO1998015647A1 (en) * 1996-10-08 1998-04-16 Novartis Ag Modulation of apoptosis
WO2001083719A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 25692, a novel human o-methyltransferase family member and uses thereof
WO2002008395A2 (en) * 2000-07-14 2002-01-31 Millennium Pharmaceuticals, Inc. Putative human methyltransferase family member and uses thereof
WO2002052016A2 (en) * 2000-12-26 2002-07-04 Bayer Aktiengesellschaft Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
GB1098347A (en) * 1964-06-29 1968-01-10 Geigy Ag J R New oxepin derivatives, their production and use
GB1080979A (en) * 1964-11-03 1967-08-31 J U Geigy A G New thiepin and wxepin derivatives
US3641056A (en) * 1970-01-06 1972-02-08 Ciba Geigy Corp 10-(aminomethyl)- and (aminoethyl)-dibenz (b f)oxepins
EP0726265A1 (en) * 1995-02-08 1996-08-14 Ciba-Geigy Ag 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity
US5780500A (en) * 1995-02-08 1998-07-14 Novartis Corporation Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines
WO1997045422A1 (en) * 1996-05-30 1997-12-04 Novartis Ag ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS
WO1998015647A1 (en) * 1996-10-08 1998-04-16 Novartis Ag Modulation of apoptosis
WO2001083719A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 25692, a novel human o-methyltransferase family member and uses thereof
WO2002008395A2 (en) * 2000-07-14 2002-01-31 Millennium Pharmaceuticals, Inc. Putative human methyltransferase family member and uses thereof
WO2002052016A2 (en) * 2000-12-26 2002-07-04 Bayer Aktiengesellschaft Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DOROTEA MÜCK-SELER ET AL: "TCH-346 novartis.", I DRUGS, vol. 3, no. 5, 2000, pages 530 - 535, XP002902887, ISSN: 1369-7056 *
HUEBSCHER K J ET AL: "Protein isoaspartyl methyltransferase protects from Bax-induced apoptosis.", GENE, vol. 240, 1999, pages 333 - 341, XP002902939, ISSN: 0378-1119 *
PERNA A F ET AL: "Metabolic consequences of Hyperhomocysteinemia in uremia.", AMERICAN JOURNAL OF KIDNEY DISEASES, vol. 38, no. 4 suppl 1, October 2001 (2001-10-01), pages s85 - s90, XP002902941, ISSN: 0272-6386 *
TSAI W ET AL: "Amino acid polymorphisms of the human L-isoaspartyl/D-aspartyl methyltransferase involved in protein repair.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 203, no. 1, 30 August 1994 (1994-08-30), pages 491 - 497, XP002902942, ISSN: 0006-291x *
XIAODONG CHENG ET AL: "Adomet- dependent methylation, DNA methyltransferases and base flipping.", NUCLEIC ACIDS RESEARCH SURVEY AND SUMMARY, vol. 29, no. 18, 2001, XP002902940 *
ZIMMERMANN K ET AL: "Dibenzoxepines as treatments for neurodegenerative diseases.", PURE APPL. CHEM., vol. 71, no. 11, 1999, pages 2039 - 2046, XP002902886 *

Also Published As

Publication number Publication date
AU2003235799A1 (en) 2003-07-24
WO2003057204A2 (en) 2003-07-17
AU2003235799A8 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
WO2003057204A3 (en) Modulation of iamt (pimt or pcmt) in immune system
AU2003278693A1 (en) Identity verification system
WO2005123277A3 (en) Optical films and methods of making the same
AU2003211192A1 (en) Meteorological observation lider system
WO2005045689A8 (en) Methods and systems for network coordination
AU2003901043A0 (en) Transaction system
WO2006107531A3 (en) Simple integration of an on-demand compute environment
WO2007022306A3 (en) Hover-buttons for user interfaces
AU2003297665A1 (en) Systems and methods for providing interactive guest resources
WO2005115522A3 (en) Medical device systems
AU2003222968A1 (en) Adeno-associated virus producer system
AU2003282740A1 (en) Dynamic menu system
ZA200202057B (en) Safety system.
AU2003220043A1 (en) Feedstock delivery system and fuel processing systems containing the same
AU2003283932A1 (en) An interventional simulator system
AU2003256248A1 (en) Dynamic security system
AU2003292766A1 (en) Armrest height-adjusting device
ZA200404607B (en) Infusion system.
WO2004048552A3 (en) Modulating immune responses
IL176211A0 (en) Quasi-one-dimensional-polymers based on the metal-chalcogen-halogen system
IL172707A0 (en) Data input device, system using the device, and methods for operating such systems
AU2003292767A1 (en) Armrest height-adjusting device
AU2003243058A1 (en) Methods for using the cd163 pathway for modulating an immune response
AU2002242175A1 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AU2003283931A1 (en) An interventional simulator system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 166377

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 166404

Country of ref document: IL

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP